IN2014MN02101A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02101A
IN2014MN02101A IN2101MUN2014A IN2014MN02101A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A IN 2101MUN2014 A IN2101MUN2014 A IN 2101MUN2014A IN 2014MN02101 A IN2014MN02101 A IN 2014MN02101A
Authority
IN
India
Prior art keywords
heart failure
present
chronic heart
stable chronic
procalcitonin
Prior art date
Application number
Inventor
Joachim Struck
John Gf Cleland
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of IN2014MN02101A publication Critical patent/IN2014MN02101A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
IN2101MUN2014 2012-04-12 2013-04-11 IN2014MN02101A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163921 2012-04-12
PCT/EP2013/057626 WO2013153177A1 (en) 2012-04-12 2013-04-11 Prognosis of adverse events in patients with suspected chronic heart failure

Publications (1)

Publication Number Publication Date
IN2014MN02101A true IN2014MN02101A (en) 2015-08-28

Family

ID=48050768

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2101MUN2014 IN2014MN02101A (en) 2012-04-12 2013-04-11

Country Status (8)

Country Link
US (3) US9488659B2 (en)
EP (1) EP2836841B1 (en)
JP (1) JP5945063B2 (en)
CN (1) CN104303061B (en)
BR (1) BR112014025189B1 (en)
IN (1) IN2014MN02101A (en)
RU (1) RU2672561C2 (en)
WO (1) WO2013153177A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02101A (en) * 2012-04-12 2015-08-28 Brahms Gmbh
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CN105929152B (en) * 2016-07-15 2018-06-26 安徽国科生物科技有限公司 A kind of intelligent detecting instrument for Procalcitonin detection
EP4421088A3 (en) * 2017-02-06 2024-12-04 Uit de Krempe IP B.V. C-peptide's interaction with elastin receptor, a blueprint for understanding vascular disease
CN108931658A (en) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 Serum markers for diagnosis of heart failure complications and prognosis
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
RU2766252C1 (en) * 2021-04-13 2022-02-10 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Method for predicting risk of death in patients with chronic heart failure using endogenous blood serum erythropoietin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
DE19847690A1 (en) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Diagnosing sepsis and severe infections, useful for assessing severity and progress of treatment, by measuring content of peptide prohormone or their derived fragments
DE102006046996A1 (en) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnosis process for respiratory infections involves using procalcitonin as marker for assessing patient risk level
CN101029897A (en) * 2007-02-09 2007-09-05 深圳市新产业生物医学工程有限公司 Calcitonin reagent unit and its testing method
DE102007009751A1 (en) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Diagnostic immunoassay for procalcitonin in a biological sample from a patient comprises selectively determining full-length procalcitonin 1-116
EP2293078B1 (en) * 2007-08-03 2011-11-09 B.R.A.H.M.S GmbH Method for diagnosis of a bacterial infection
EP2101178A1 (en) * 2008-03-12 2009-09-16 BRAHMS Aktiengesellschaft Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes
RU2357250C1 (en) * 2007-12-10 2009-05-27 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Chronic cardial insufficiency course prediction method
PT2419741T (en) * 2009-04-14 2019-11-04 Brahms Gmbh Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
EP2284540A1 (en) * 2009-07-31 2011-02-16 BIOCRATES Life Sciences AG Method of diagnosing organ failure
CN201886025U (en) * 2010-12-10 2011-06-29 四川迈克生物科技股份有限公司 Immunochromatography strip for rapidly and quantitatively detecting procalcitonin
IN2014MN02101A (en) * 2012-04-12 2015-08-28 Brahms Gmbh

Also Published As

Publication number Publication date
CN104303061A (en) 2015-01-21
BR112014025189A2 (en) 2017-07-11
JP5945063B2 (en) 2016-07-05
WO2013153177A1 (en) 2013-10-17
US20150079696A1 (en) 2015-03-19
US9488659B2 (en) 2016-11-08
EP2836841B1 (en) 2022-01-05
US20170370940A1 (en) 2017-12-28
RU2014145259A (en) 2016-06-10
US9753039B2 (en) 2017-09-05
US20160320411A1 (en) 2016-11-03
CN104303061B (en) 2017-05-31
RU2672561C2 (en) 2018-11-16
HK1203611A1 (en) 2015-10-30
BR112014025189B1 (en) 2020-04-07
JP2015515630A (en) 2015-05-28
EP2836841A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
IN2014MN02101A (en)
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
MX367046B (en) Pathway specific markers for diagnosing irritable bowel syndrome.
EA201391187A1 (en) METHOD OF DIAGNOSTICS OF MALIGNANT TUMOR AND A SET FOR DIAGNOSTICS BY MEASURING NK-CELL ACTIVITY
MX339427B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer.
UA109271C2 (en) COMBINATION OF PHYTOCANABINOIDS AND THEMOSOLAMIDE FOR THE TREATMENT OF GLIOMA
UA116196C2 (en) Synthetic apelin mimetics for the treatment of heart failure
MX347454B (en) Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
PH12014501176A1 (en) Anticoagulant reversal agents
MX343801B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer.
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EA201490883A1 (en) APPLICATION OF ANTIBODIES TO α-SINUCULINE FOR DIAGNOSTIC OF THE INCREASED LEVEL OF α-SINUCLEIN IN THE BRAIN
BR112012016894A2 (en) lactobacilli with antioxidant action.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
EA201591773A1 (en) MACRO CYCLIC INHIBITORS RIP2-KINASE
MX368474B (en) Methods for improving asthma symptoms using benralizumab.
AU2012313353A8 (en) Screening method
EA201270315A1 (en) NEW FORMS OF POLYCYCLIC CONNECTION
HK1215069A1 (en) Determination of location of bacterial load in the lungs
IN2014DN08312A (en)
HUE042708T2 (en) Diagnosis of heart failure
MY170453A (en) Etching material
EA201391772A1 (en) METHOD OF DIAGNOSTIC RHEUMATOID ARTHRITIS